Downstream inhibition of the PI3K pathway by targeting of mechanistic target of rapamycin (mTOR) is currently possible with agents such as Sirolimus, already used in clinical practice for prevention of organ allograft rejection, for the treatment of autoimmune disorders and some cancers, and, more recently, for precision therapy for tuberous sclerosis complex [50]. This evidence concerns the gene PIK3CA and cancer.